Navigation Links
Retinol for combating leukemia cells

Some ten years ago the Department of Cell Biology and Histology at the University of the Basque Country initiated research into how cell death was boosted by means of retinoids. It was thought that this potential could be used in the fight against cancer cells.

Vitamin A, also known as retinol, is present in milk, liver, egg yolk, butter and other foodstuffs and as carotene in vegetables that have a yellow-orange colour, such as carrots and pumpkins.

This vitamin is accumulated in the liver where it is transformed into retinoid. Given that vitamin A, as such, has no effect on our organism, it is the retinoids that are responsible for the physiological activity of the vitamin.

Retinoids take part in three processes: in cell death, in cell differentiation and in cell proliferation.

Clean and programmed death

Two types of death occur in cells: necrosis and apoptosis. Necrosis defines a pathological death, i.e. a death caused by a lack or deficit within the cell such as lack of oxygen or food.

On the other hand, apoptosis is the pre-programmed death of a cell. A number of cells have to die in order that our organism function correctly: for example, when the feet of a foetus are developed in the womb of a mother, at first the fingers are united by a membrane. This membrane has to disappear and, so, the cells thereof have to die off so that the hands may develop correctly. This cellular death is programmed in the embryo genes and has a concrete function. This is apoptosis.

All cells, in fact, have the necessary information to be able to undergo apoptosis but, of course, not all cells have to die. Both internal and external stimuli are what initiate this mechanism in those cases where it is necessary. Various modulating substances are involved amongst which are the retinoids.

Boosting apoptosis

Amongst these retinoids, researchers from the University of the Basque Country chose retinam ide for their investigations. Retinamide is a synthetic retinoid, i.e. our body does not produce this substance naturally.

Natural retinoids are used to treat various diseases (e.g. those of the skin) but they turn out to be quite poisonous in the doses required ?they are not well tolerated. This is why synthetic retinoids are created.

Specifically, the University research team analysed the effect of retinamide in certain types of leukemia - lymphoblastic leukemias. Nowadays, samples from the Hospital de Cruces in Bilbao are used in order to get these types of leukemia cells.

Lymphoblastic leukemias are, as their name indicates, a type of leukemia that affects lymphoblasts. Lymphoblasts are large cells, precursors of lymphocytes. Malign lymphoblasts are constantly dividing and they accumulate in the bone marrow impeding the formation of blood cells. In the analyses undertaken in the laboratory, it was seen that 95 % of these malign lymphoblasts died after application of retinamide. But what is the mechanism that really triggers this death?

To explain the process, the researchers analysed the action mechanism of the retinamide at a molecular level. From the analyses it was observed that the retinamide accelerated the oxidative stress within the malign cells and that this stress triggered the mechanisms leading to apoptosis. This death is normally clean and programmed death, and, to this end, a group of enzymes cut the protein inside the cell at certain sites, leading to the death of the cell in question. The death has no effect on healthy adjacent cells, does not result in swelling and the side effects are minimal.

Thus, according to what has been shown, retinamide has great potential to eliminate the lymphoblastic cells without affecting healthy lymphocytes nor the rest of the normal cells.

Made-to-measure treatment

With the molecular action mechanism understood, researchers investigated why retinamide did not affect healthy cells and they discovered other factors to explain the phenomena. So, apart from molecular mechanisms, other factors that affect the efficacy of retinamide could be clearly seen. These and others should be taken into account if a pharmaceutical to combat leukemias based on retinamide is to be marketed.

Moreover, according to the researchers, future treatment will be patient-specific. As is well known, not all patients suffering from the same illness respond in the same way to the same treatment. This is why lines of medical and pharmaceutical research increasingly mention the need to know the genetic characteristics of each patient in order to specify suitable treatment. In the case of retinamide, treatment will also be similarly specific but, before this, the trigger mechanism of the retinamide in the cells has to be known and this research will provide key data to this end.


'"/>

Source:Elhuyar Fundazioa


Related biology news :

1. Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases
2. Asleep in the deep: Model helps assess ocean-injection strategy for combating greenhouse effect
3. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
4. Genome-wide mouse study yields link to human leukemia
5. Enzyme allows B cells to resist death, leading to leukemia
6. Genetically modified natural killer immune cells attack, kill leukemia cells
7. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
8. Genes linked to treatment resistance in children with leukemia
9. Mouse mimics chronic leukemia, will aid drug development
10. Pair of microRNA molecules controls major oncogene in most common leukemia
11. Tribbles protein implicated in common and aggressive form of leukemia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... Minneapolis, MN (PRWEB) , ... July 26, 2017 ... ... All of Us Research Program at the National Institutes of Health (NIH), will ... Medicine Conference. This annual conference provides a platform for a multi-stakeholder discussion on ...
(Date:7/25/2017)... Canaan, CT (PRWEB) , ... July 25, 2017 ... ... sustainable products that enhance the microbiome and improve efficiency of livestock farming while ... announced that it has licensed additional intellectual property from Cornell University. , ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Arnold and Mabel Beckman ... of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology, as ... recognizes an individual who has made and is continuing to make significant transformative ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... seminar on digital pathology and artificial intelligence Tuesday, July 25, during the Association ... Baras from Johns Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, ...
Breaking Biology Technology: